% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Nov 1, 2013 2:32 PM Flag

    Comet1 estimated completion

    Nice little write-up on Comet 1 @ targetedoncdotcom...posted 11/1/13
    "The 960-patient trial is under way at 270 sites worldwide and has an estimated primary completion date of March 2014. In preclinical studies, cabozantinib has shown powerful tumoricidal, antimetastatic, and antiangiogenic effects, including extensive apoptosis of malignant cells, decreased tumor invasiveness and metastasis, decreased tumor and endothelial cell proliferation, blockade of metastatic bone lesion progression, and disruption of tumor vasculature."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
4.200.00(0.00%)Feb 12 4:00 PMEST